Prurigo Nodularis clinical trials

Explore recruiting prurigo nodularis clinical trials.

Recruiting prurigo nodularis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Prurigo Nodularis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

INCB 18424-320: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Prurigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN2)

Austria, Poland, Spain, France, Bulgaria, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

France, Bulgaria, Netherlands, Poland, Austria, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

Sweden, Germany, Spain, Denmark, Belgium, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CDX0159-10: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo Nodularis

Spain, Germany, Poland, Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies

Greece, Hungary, Romania, Spain, France, Sweden +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis

Belgium, Poland, Germany, France, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Prurigo Nodularis trials by city

Prurigo Nodularis in Toronto Prurigo Nodularis in Vancouver Prurigo Nodularis in Montreal Prurigo Nodularis in Calgary Prurigo Nodularis in Edmonton Prurigo Nodularis in Ottawa Prurigo Nodularis in Winnipeg Prurigo Nodularis in Quebec City Prurigo Nodularis in Hamilton Prurigo Nodularis in Kitchener Prurigo Nodularis in London Prurigo Nodularis in Halifax Prurigo Nodularis in New York Prurigo Nodularis in Los Angeles Prurigo Nodularis in Chicago Prurigo Nodularis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease